Skip to main content
Clinical Trials/NCT01355146
NCT01355146CompletedNot Applicable

Non Interventional Study of Replagal® Home Therapy in Patients With Fabry Disease

Shire22 sites in 2 countries127 target enrollmentStarted: March 15, 2011Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Shire
Enrollment
127
Locations
22
Primary Endpoint
Patient satisfaction estimated on a 10-ary Likert scale

Study Overview

Brief Summary

The purpose of this study is to proof increasing patient satisfaction and preservation of quality of life in patients with Morbus Fabry disease receiving their Enzyme Replacement Therapy with Replagal (Agalsidase alfa) at home compared to receiving the infusions at the clinic or at doctor's practice.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
4 Years to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Patient/legal representative does not give consent to participation in this study
  • Patient/legal representative declines Replagal® home therapy
  • The patient is participating in a clinical trial with a medicinal product

Outcomes

Primary Outcomes

Patient satisfaction estimated on a 10-ary Likert scale

Time Frame: comparison of baseline to 12 months value

Secondary Outcomes

  • Number (per infusion) and severity of infusion-related side effects(baseline compared to 12 months)

Investigators

Sponsor
Shire
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (22)

Loading locations...

Similar Trials

Home Therapy With Replagal in Fabry Disease | Clinical Trial